You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation
|
|---|---|
| Published in |
JACC, November 2017
|
| DOI | 10.1016/j.jacc.2017.09.1087 |
| Pubmed ID | |
| Authors |
Xiaoxi Yao, Navdeep Tangri, Bernard J. Gersh, Lindsey R. Sangaralingham, Nilay D. Shah, Karl A. Nath, Peter A. Noseworthy |
| Abstract |
Lifelong oral anticoagulation, either with warfarin or a non-vitamin K antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with atrial fibrillation (AF). Emerging evidence suggests that NOACs may be associated with better renal outcomes than warfarin. This study aimed to compare 4 oral anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for their effects on 4 renal outcomes: ≥30% decline in estimated glomerular filtration rate (eGFR), doubling of the serum creatinine level, acute kidney injury (AKI), and kidney failure. Using a large U.S. administrative database linked to laboratory results, the authors identified 9,769 patients with nonvalvular AF who started taking an oral anticoagulant agent between October 1, 2010 and April 30, 2016. Inverse probability of treatment weighting was used to balance more than 60 baseline characteristics among patients in the 4 drug cohorts. Cox proportional hazards regression was performed in the weighted population to compare oral anticoagulant agents. The cumulative risk at the end of 2 years for each outcome was 24.4%, 4.0%, 14.8%, and 1.7% for ≥30% decline in eGFR, doubling of serum creatinine, AKI, and kidney failure, respectively. When the 3 NOACs were pooled, they were associated with reduced risks of ≥30% decline in eGFR (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0.66 to 0.89; p < 0.001), doubling of serum creatinine (HR: 0.62; 95% CI: 0.40 to 0.95; p = 0.03), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p < 0.001) compared with warfarin. When comparing each NOAC with warfarin, dabigatran was associated with lower risks of ≥30% decline in eGFR and AKI; rivaroxaban was associated with lower risks of ≥30% decline in eGFR, doubling of serum creatinine, and AKI; however, apixaban did not have a statistically significant relationship with any of the renal outcomes. Renal function decline is common among patients with AF treated with oral anticoagulant agents. NOACs, particularly dabigatran and rivaroxaban, may be associated with lower risks of adverse renal outcomes than warfarin. |
X Demographics
The data shown below were collected from the profiles of 255 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 57 | 22% |
| United States | 23 | 9% |
| Venezuela, Bolivarian Republic of | 11 | 4% |
| United Kingdom | 8 | 3% |
| Mexico | 7 | 3% |
| Chile | 5 | 2% |
| Ecuador | 5 | 2% |
| Colombia | 3 | 1% |
| Peru | 3 | 1% |
| Other | 31 | 12% |
| Unknown | 102 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 184 | 72% |
| Practitioners (doctors, other healthcare professionals) | 43 | 17% |
| Scientists | 23 | 9% |
| Science communicators (journalists, bloggers, editors) | 5 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 204 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 204 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 25 | 12% |
| Researcher | 23 | 11% |
| Student > Ph. D. Student | 19 | 9% |
| Student > Master | 19 | 9% |
| Student > Bachelor | 15 | 7% |
| Other | 34 | 17% |
| Unknown | 69 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 74 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 8% |
| Nursing and Health Professions | 8 | 4% |
| Agricultural and Biological Sciences | 7 | 3% |
| Social Sciences | 3 | 1% |
| Other | 12 | 6% |
| Unknown | 83 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 229. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2021.
All research outputs
#170,918
of 25,887,951 outputs
Outputs from JACC
#373
of 16,985 outputs
Outputs of similar age
#3,509
of 343,913 outputs
Outputs of similar age from JACC
#15
of 279 outputs
Altmetric has tracked 25,887,951 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,985 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,913 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 279 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.